CSL Limited Annual Report 2022/23 31 CSL’s new R&D campus, in Marburg, Germany opened its doors in September 2022 and is now home to about 500 CSL R&D employees. In addition, it will host academic partners and collaborators. CSL’s new Plasma Fractionation Facility opened in Broadmeadows, Victoria in December 2022. It is the largest of its kind in the Southern Hemisphere and is part of CSL’s multi-billion dollar investment in Australia – reinforcing CSL’s commitment to patients. The facility will process domestic plasma from Australian, New Zealand, Taiwanese, Hong Kong and Malaysian donor plasma, in addition to commercially sourced plasma through CSL Plasma, one of the world’s largest collectors of human plasma. A new state-of-the art R&D centre in Waltham, Massachusetts, in the United States, officially opened in March 2023 and will support CSL’s growing R&D portfolio, including the next-generation mRNA technology platform for seasonal and pandemic influenza vaccines. Tullamarine Broadmeadows United States Waltham Germany Marburg CSL’s newmanufacturing facility under construction in the Melbourne Airport Business Park in Tullamarine, is set to be Australia’s latest world-class biotech manufacturing facility and the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere when it opens in mid-2026. The facility will also manufacture seasonal and pandemic influenza vaccines, CSL Seqirus’ proprietary adjuvant MF59® and unique products of national significance important to Australia’s public health needs. Australia Melbourne Pictured left, is CSL Melbourne, CSL’s new Global Headquarters and Centre for R&D located in the heart of the Melbourne Biomedical Precinct.
RkJQdWJsaXNoZXIy MjE2NDg3